Literature DB >> 18475311

Association of urinary N-domain Angiotensin I-converting enzyme with plasma inflammatory markers and endothelial function.

Fernanda B Fernandes1, Frida L Plavnik, Andressa Ms Teixeira, Dejaldo Mj Christofalo, Sergio A Ajzen, Elisa Ms Higa, Fernanda A Ronchi, Ricardo Cc Sesso, Dulce E Casarini.   

Abstract

The aim of this study was to investigate the association between urinary 90 kDa N-domain Angiotensin I-converting enzyme (ACE) form with C-reactive protein (CRP) and homocysteine plasma levels (Hcy), urinary nitric oxide (NOu), and endothelial function (EF) in normotensive subjects. Forty healthy subjects were evaluated through brachial Doppler US to test the response to reactive hyperemia and a panel of blood tests to determine CRP and Hcy levels, NOu, and urinary ACE. They were divided into groups according to the presence (ACE90+) or absence (ACE90-) of the 90 kDa ACE, the presence (FH+) or absence (FH-) of family history of hypertension, and the presence or absence of these two variables FH+/ACE90+ and FH-/ACE90-. We found an impaired endothelial dilatation in subjects who presented the 90 kDa N-domain ACE as follows: 11.4% +/- 5.3% in ACE90+ compared with 17.6% +/- 7.1% in ACE90- group and 12.4% +/- 5.6% in FH+/ACE90+ compared with 17.7% +/- 6.2% in FH-/ACE90- group, P < 0.05. Hcy and CRP levels were statistically significantly lower in FH+/ACE90+ than in FH-/ACE90- group, as follows: 10.0 +/- 2.3 microM compared with 12.7 +/- 1.5 microM, and 1.3 +/- 1.8 mg/L compared with 3.6 +/- 2.0 mg/L, respectively. A correlation between flow-mediated dilatation (FMD) and CRP, Hcy, and NOu levels was not found. Our study suggests a reduction in the basal NO production confirmed by NOu analysis in subjects with the 90 kDa N-domain ACE isoform alone or associated with a family history of hypertension. Our data suggest that the presence of the 90 kDa N-domain ACE itself may have a negative impact on flow-mediated dilatation stimulated by reactive hyperemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18475311      PMCID: PMC2376638          DOI: 10.2119/2007-00112.Fernandes

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  42 in total

Review 1.  Hyperhomocysteinemia in terms of steady-state kinetics.

Authors:  H Refsum; A B Guttormsen; T Fiskerstrand; P M Ueland
Journal:  Eur J Pediatr       Date:  1998-04       Impact factor: 3.183

2.  Rapid and accurate HPLC assay for plasma total homocysteine and cysteine in a clinical laboratory setting.

Authors:  C M Pfeiffer; D L Huff; E W Gunter
Journal:  Clin Chem       Date:  1999-02       Impact factor: 8.327

3.  Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability.

Authors:  Brian R Clapp; Gideon M Hirschfield; Clare Storry; J Ruth Gallimore; Ray P Stidwill; Mervyn Singer; John E Deanfield; Raymond J MacAllister; Mark B Pepys; Patrick Vallance; Aroon D Hingorani
Journal:  Circulation       Date:  2005-03-29       Impact factor: 29.690

Review 4.  The vascular biology of nitric oxide and its role in atherogenesis.

Authors:  D M Lloyd-Jones; K D Bloch
Journal:  Annu Rev Med       Date:  1996       Impact factor: 13.739

5.  Basal nitric oxide production is impaired in offspring of patients with essential hypertension.

Authors:  A S McAllister; A B Atkinson; G D Johnston; D R Hadden; P M Bell; D R McCance
Journal:  Clin Sci (Lond)       Date:  1999-08       Impact factor: 6.124

Review 6.  Signaling by the angiotensin-converting enzyme.

Authors:  Ingrid Fleming
Journal:  Circ Res       Date:  2006-04-14       Impact factor: 17.367

Review 7.  Molecular genetics of human hypertension.

Authors:  F C Luft
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

8.  Alternative splicing of the mRNA coding for the human endothelial angiotensin-converting enzyme: a new mechanism for solubilization.

Authors:  K Sugimura; X L Tian; S Hoffmann; D Ganten; M Bader
Journal:  Biochem Biophys Res Commun       Date:  1998-06-18       Impact factor: 3.575

9.  A study of chimeras constructed with the two domains of angiotensin I-converting enzyme.

Authors:  T A Williams; S Danilov; F Alhenc-Gelas; F Soubrier
Journal:  Biochem Pharmacol       Date:  1996-01-12       Impact factor: 5.858

10.  The preparation and function of the hypertensin-converting enzyme.

Authors:  L T SKEGGS; J R KAHN; N P SHUMWAY
Journal:  J Exp Med       Date:  1956-03-01       Impact factor: 14.307

View more
  1 in total

1.  N-domain isoform of Angiotensin I converting enzyme as a marker of hypertension: populational study.

Authors:  Leila C V Maluf-Meiken; Fernanda B Fernandes; Danielle S Aragão; Fernanda A Ronchi; Maria C C Andrade; Maria C Franco; Andreia C S Febba; Frida L Plavnik; José E Krieger; Jose G Mill; Ricardo C C Sesso; Dulce E Casarini
Journal:  Int J Hypertens       Date:  2012-05-15       Impact factor: 2.420

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.